The role of prenatal diagnosis following preimplantation genetic testing for single‐gene conditions: A historical overview of evolving technologies and clinical practice

Abstract Preimplantation genetic testing for monogenic conditions (PGT‐M) has become a valued reproductive option for couples at risk of having a child with a single gene condition. In line with developments in molecular genetics, there has been an overall trend toward laboratory techniques with higher accuracy in comparison to earlier PGT‐M techniques. The recommendation for confirmatory prenatal diagnostic testing has remained a standard component of PGT‐M counseling, reflecting the inherent difficulties of testing the limited number of cells obtained from embryo biopsy, as well as recognition of the biological and human factors that may lead to misdiagnosis in a PGT‐M cycle. Reported misdiagnosis rates are less than 1 in 200 pregnancies following PGT‐M, although updated data regarding newer methods of PGT‐M are required. There is limited evidence available regarding clinician and patient behavior in pregnancies resulting from PGT‐M cycles. It remains essential that clinicians involved in the care of patients undergoing PGT‐M provide appropriate counseling regarding the risks of misdiagnosis and the importance of confirmatory prenatal diagnosis. The nature of PGT‐M test design lends itself to cell‐free DNA‐based noninvasive prenatal testing for monogenic conditions (NIPT‐M), which is likely to become a popular method in the near future.